ChiCTR2300075388: Clinical study of trilaciclib for the prevention of severe myelosuppression after chemotherapy in patients with bone and soft tissue sarcoma |
|
|
| Recruiting | 4 | 550 | | Patients with bone and soft tissue sarcoma who had IV-degree bone marrow suppression in previous chemotherapy did not receive Turacilli for preventive treatment. ;Patients with bone and soft tissue sarcoma who have experienced IV-degree bone marrow inhibition in chemotherapy should receive trarasili (240 mg/m2, intravenous administration within 4 hours before chemotherapy, and the number of days of medication is determined according to the number of days of chemotherapy) before the next chemotherapy. ;Patients with bone and soft tissue sarcoma will not receive prophylactic treatment until they plan to receive a high-risk chemotherapy regimen. ;Before patients with bone and soft tissue sarcoma are proposed to receive high-FN-risk chemotherapy, trarasili (240 mg/m2, intravenous administration within 4 hours before chemotherapy, and the number of days of medication is determined according to the number of days of chemotherapy) for preventive treatment. | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Self-finance | Bone and soft tissue sarcoma | | | | |
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
|
|
| Recruiting | 2 | 5000 | US | Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole | QuantumLeap Healthcare Collaborative | Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer | 12/30 | 12/31 | | |